Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN versus PIROXICAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN versus PIROXICAM.
Aspirin vs PIROXICAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) via acetylation, reducing prostaglandin and thromboxane A2 synthesis. Also activates lipoxin biosynthesis (inflammation resolution).
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
325-650 mg PO q4-6h prn; max 4 g/day
10-20 mg orally once daily; maximum 20 mg/day.
None Documented
None Documented
30 minutes for aspirin (parent drug); salicylic acid: 2-3 hours after low doses, 15-30 hours after high doses due to saturable metabolism and renal reabsorption. Clinical context: prolonged half-life in overdose, renal impairment, and elderly patients.
Clinical Note
moderatePiroxicam + Gatifloxacin
"Piroxicam may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePiroxicam + Rosoxacin
"Piroxicam may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePiroxicam + Levofloxacin
"Piroxicam may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePiroxicam + Trovafloxacin
"Piroxicam may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is 50 hours (range 30-86 hours), allowing once-daily dosing. Prolonged in elderly (up to 80 hours) and in hepatic impairment.
Renal excretion of salicylates (75-85% as salicyluric acid, 10% as free salicylic acid, 5-10% as glucuronide conjugates); dose-dependent, with renal clearance decreasing at higher doses due to saturation of metabolic pathways. Biliary/fecal elimination is minimal (<5%).
Approximately 60-70% renal (glomerular filtration and tubular secretion) as unchanged drug and metabolites; 30-40% fecal via biliary excretion. Less than 5% as unchanged drug in urine.
Category C
Category D/X
NSAID / Antiplatelet
NSAID